Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419003 · ClinicalTrials.gov registry record · Phase 4
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT00419003 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 26 participants.
The verdict
NCT00419003, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.
Interventions
- DRUG Ketamine
- DRUG Lamotrigine
- DRUG Riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419003
The ClinicalTrials.gov registry entry for NCT00419003 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT00419003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419003 about?
NCT00419003 is a clinical study titled "Research Study for Major Depressive Disorder: Investigation of Glutamate Medications". This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects ...
What is the current status of trial NCT00419003?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2006-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00419003?
The interventions under investigation include: Ketamine (DRUG), Lamotrigine (DRUG), Riluzole (DRUG).
Who is sponsoring clinical trial NCT00419003?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.